Vanguard Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Vanguard Group’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$3.51M	Buy	266,150 +145,907	+121%	+$1.72M	﹤0.01%	3384
2025 Q3	$862K	Sell	120,243 -626	-0.5%	-$32.6K	﹤0.01%	3828
2025 Q2	$5.71M	Buy	120,869 +6,851	+6%	+$279K	﹤0.01%	3168
2025 Q1	$4.45M	Sell	114,018 -1,398	-1%	-$60.2K	﹤0.01%	3224
2024 Q4	$6.25M	Sell	115,416 -2,320	-2%	-$118K	﹤0.01%	3176
2024 Q3	$5.94M	Buy	117,736 +25,896	+28%	+$1.21M	﹤0.01%	3201
2024 Q2	$4.04M	Sell	91,840 -458	-0.5%	-$19.4K	﹤0.01%	3346
2024 Q1	$4.64M	Buy	92,298 +18,641	+25%	+$1.01M	﹤0.01%	3327
2023 Q4	$4.45M	Buy	73,657 +60,066	+442%	+$3.1M	﹤0.01%	3336
2023 Q3	$775K	Buy	+13,591	New	+$750K	﹤0.01%	3922

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group's MLTX Position: Q4 2025 in Review

Vanguard Group increased its MoonLake Immunotherapeutics (MLTX) stake by 121% in Q4 2025, buying an estimated $1.72M and bringing the position to 266,150 shares worth $3.51M. The position accounts for ﹤0.01% of the portfolio, ranked #3384.

Vanguard Group first reported a position in MLTX in Q3 2023 and has held it in 10 quarters since. The position peaked at $6.25M in Q4 2024. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

Vanguard Group held 266,150 shares of MoonLake Immunotherapeutics worth $3.51M as of Q4 2025.
Vanguard Group bought 145,907 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $1.72M.
MoonLake Immunotherapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3384 holding.
Vanguard Group first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 10 quarters since.
Vanguard Group's MoonLake Immunotherapeutics position peaked at $6.25M in Q4 2024.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.